Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Evox Therapeutics Ltd.
Headquarters: Oxford, United Kingdom
Website: http://www.evoxtherapeutics.c...
Year Founded: 2016
Status: Private
BioCentury | Jan 15, 2025
Management Tracks
Auspitz becomes managing partner at Curie.bio
Plus: Amphista names Paul Medeiro CBO, and updates from Apellis, Forbion, Eqt, Egle, Spero, Molecular Templates and more
BioCentury | Jul 30, 2024
Product Development
Venturing beyond AAVs and LNPs to deliver therapeutic cargo
Dozens of companies aim to avoid immunogenicity and improve tissue-specificity
BioCentury | Jul 3, 2024
Management Tracks
CSO Kilty replaces Weir as Sitryx CEO
Plus: Y-mAbs hires Peter Pfreundschuh as CFO, and updates from LIfT,
BioCentury | Apr 30, 2024
Management Tracks
New CEOs at Evox and George Medicines
Plus: Stoke hires Thomas Leggett as CFO, and updates from TScan, Rinri, Tevogen and more
BioCentury | Sep 28, 2023
Management Tracks
Expanded role for Gaito at J.P. Morgan
Plus: Peptone hires a new CSO, names Gritstone’s Allen chair, and updates from Foresite, OncoC4, Sibylla, Cell-Easy and Photocure
BioCentury | Nov 15, 2022
Finance
Nov. 15 Quick Takes: Panacea to deploy $276M in pair of funds
Plus: Acrivon’s IPO; fundings for Bonum, CG Oncology and Jnana; and pipeline updates from Arcutis and Everest
BioCentury | Dec 1, 2021
Discovery & Translation
Two applications of omics-based biomarkers in cancer; plus Evox, Akoya and more
BioCentury’s roundup of translational news
BioCentury | Oct 26, 2021
Data Byte
Two years of gene therapy dealmaking
AAVs still center stage, but next-gen approaches starting to attract more partners
BioCentury | Oct 9, 2021
Discovery & Translation
Improved guide RNAs for prime editing; plus J&J, Synlogic and more
BioCentury’s roundup of translational news
BioCentury | May 28, 2021
Product Development
Exosomes: a case study in manufacturing a new modality at scale
Exosome companies are anchoring their plans for progress in manufacturing innovation
Items per page:
1 - 10 of 31